Do all cardiac surgery patients benefit from antifibrinolytic therapy ?

2021 ◽  
Vol 36 (4) ◽  
pp. 1450-1457
Author(s):  
Matthew S. Sussman ◽  
Eva M. Urrechaga ◽  
Alessia C. Cioci ◽  
Rahul S. Iyengar ◽  
Tyler J. Herrington ◽  
...  
2019 ◽  
Vol 229 (4) ◽  
pp. S44-S45
Author(s):  
Matthew Sussman ◽  
Michelle B. Mulder ◽  
Emily L. Ryon ◽  
Hogan Brecount ◽  
Stephen P. Wittels ◽  
...  

1998 ◽  
Vol 86 (Supplement) ◽  
pp. 105SCA
Author(s):  
GA Nuttall ◽  
WC Oliver ◽  
MH Ereth ◽  
PJ Santrach ◽  
TA Orszulak ◽  
...  

1996 ◽  
Vol 9 (1) ◽  
pp. 46-53
Author(s):  
Nicholas Harper ◽  
David Royston

2020 ◽  
Author(s):  
Matthew Sussman ◽  
Eva Urrechaga ◽  
Alessia Cioci ◽  
Rahul Iyengar ◽  
Tyler Herrington ◽  
...  

2015 ◽  
Vol 123 (1) ◽  
pp. 214-221 ◽  
Author(s):  
Andreas Koster ◽  
David Faraoni ◽  
Jerrold H. Levy

Abstract Antifibrinolytic therapy reduces bleeding and chest tube drainage output in cardiac surgical patients but is associated with potential side effects. Two phase-II studies with new compounds were terminated prematurely. There is increasing evidence of adverse side effects with tranexamic acid.


Sign in / Sign up

Export Citation Format

Share Document